LIR Life Sciences Corp.
BBCMF
$0.07
-$0.18-73.76%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 01/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | 7.30K | -- | |
| Gross Profit | -- | -- | -7.30K | -- | |
| SG&A Expenses | 1.38M | 140.40K | 93.80K | 82.20K | |
| Depreciation & Amortization | 1.00K | 1.00K | 800.00 | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 1.39M | 141.40K | 101.90K | 82.20K | |
| Operating Income | -1.39M | -141.40K | -101.90K | -82.20K | |
| Income Before Tax | -1.60M | -141.20K | -102.00K | -82.20K | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -1.60M | -141.20K | -102.00K | -82.20K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -1.60M | -141.20K | -102.00K | -82.20K | |
| EBIT | -1.39M | -141.40K | -101.90K | -82.20K | |
| EBITDA | -1.39M | -140.40K | -101.10K | -- | |
| EPS Basic | -0.06 | -0.01 | -0.01 | -0.02 | |
| Normalized Basic EPS | -0.04 | 0.00 | 0.00 | -0.02 | |
| EPS Diluted | -0.06 | -0.01 | -0.01 | -0.02 | |
| Normalized Diluted EPS | -0.04 | 0.00 | 0.00 | -0.02 | |
| Average Basic Shares Outstanding | 27.69M | 19.39M | 19.00M | 3.40M | |
| Average Diluted Shares Outstanding | 27.69M | 19.39M | 19.00M | 3.40M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |